Agreed Tadasana. Also, and this needs repeating. The combination therapy has always been stated by both Liau and Prins, as the focus for extending the treatment benefits to the other patients, for a longer term survival. I don't think she is shooting for 2 or 3 or 6 months additional life in these trials and she has no idea if that will be the case for the other patients of not, which would still be significant for them most likely. And I'm just throwing those numbers out to make a point. Given the challenge with the crossover and the placebo, they are feeling in the dark even though we know they can see this long tail. That's the big problem with this kind of trial and also with the fact that they were early, and had to offer the crossover option at that early stage to get people to try DCVax.
There is no difference between yesterday and today. She's a lovely person and doctor and is just doing her best.
Market Data 
Markets 
AI
